Center for Complementary Medicine, Department of Environmental Health Sciences, University Medical Center Freiburg, Freiburg, Germany.
Planta Med. 2012 Mar;78(4):334-40. doi: 10.1055/s-0031-1280455. Epub 2011 Dec 22.
This study aimed to investigate the immunomodulatory and antiallergic properties of preparations from lemon, Citrus medica L. (citrus), and quince, Cydonia oblonga Mill. (Cydonia), which are used in pharmaceutical products to treat patients suffering from allergic disorders. Preparations were analyzed with respect to their impact on the degranulation capacity from basophilic cells as well as mediator release from activated human mast cells in vitro, including IL-8 and TNF- α secretion. The results show that the degranulation of basophilic cells was diminished only in the presence of Citrus, and this effect was compared to the synthetic drug azelastine. Furthermore, Citrus and Cydonia both inhibited the production of IL-8 and TNF- α from human mast cells, and at low concentrations additive effects were observed. As a positive inhibition control, dexamethasone was used. LC-MS analyses showed that the major phenolic components in extracts from Citrus and Cydonia are eriocitrin and neochlorogenic acid, respectively. Nevertheless, these compounds do not show biological effects at concentration levels detected in their corresponding extracts. In conclusion, the present data provide a rational base for the use of the single pharmaceutical preparations from Citrus and Cydonia in a differentiated treatment of allergic disorders in part by the regulation of soluble allergic mediators from basophilic cells and mast cells.
本研究旨在探究柠檬（Citrus medica L.）和榅桲（Cydonia oblonga Mill.）制剂的免疫调节和抗过敏特性。这些制剂在药物产品中被用于治疗患有过敏疾病的患者。我们分析了这些制剂对体外嗜碱性粒细胞脱颗粒能力以及激活的人肥大细胞介质释放（包括 IL-8 和 TNF-α 分泌）的影响。结果表明，只有在存在柠檬的情况下，嗜碱性粒细胞的脱颗粒才会减少，并且这种作用可与合成药物氮卓斯汀（azelastine）相媲美。此外，柠檬和榅桲均抑制人肥大细胞产生 IL-8 和 TNF-α，并且在低浓度下观察到相加作用。作为阳性抑制对照，使用了地塞米松（dexamethasone）。LC-MS 分析表明，柠檬和榅桲提取物中的主要酚类成分分别是橙皮苷和新绿原酸。然而，这些化合物在其相应提取物中检测到的浓度水平下不显示生物效应。总之，本研究数据为柠檬和榅桲的单一药物制剂在部分通过调节嗜碱性粒细胞和肥大细胞的可溶性过敏介质来差异化治疗过敏疾病方面的使用提供了合理依据。
